Literature DB >> 19210699

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.

M A Ghannoum1, A Chen, M Buhari, J Chandra, P K Mukherjee, D Baxa, A Golembieski, J A Vazquez.   

Abstract

Recent studies suggest that differences in antifungal activity among echinocandins may exist. In this study, the activities of three echinocandins (anidulafungin, caspofungin, and micafungin) against Candida parapsilosis isolates from burn unit patients, healthcare workers and the hospital environment were determined. Additionally, the effect of these echinocandins on the cell morphology of caspofungin-susceptible and caspofungin-non-susceptible isolates was assessed using scanning electron microscopy (SEM). The C. parapsilosis isolates obtained from patients were susceptible to anidulafungin, but were less so to caspofungin and micafungin. Isolates obtained from healthcare workers or environmental sources were susceptible to all antifungals. SEM data demonstrated that although anidulafungin and caspofungin were equally active against a caspofungin-susceptible C. parapsilosis strain, they differed in their ability to damage a caspofungin-non-susceptible strain, for which lower concentrations of anidulafungin (1 mg/L) than of caspofungin (16 mg/L) were needed to induce cellular damage and distortion of the cellular morphology. To determine whether the difference in the antifungal susceptibility of C. parapsilosis isolates to anidulafungin as compared to the other two echinocandins could be due to different mutations in the FKS1 gene, the sequences of the 493-bp region of this gene associated with echinocandin resistance were compared. No differences in the corresponding amino acid sequences were observed, indicating that differences in activity between anidulafungin and the other echinocandins are not related to mutations in this region. The results of this study provide evidence that differences exist between the activities of anidulafungin and the other echinocandins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210699     DOI: 10.1111/j.1469-0691.2008.02660.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  18 in total

1.  Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.

Authors:  A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

2.  Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.

Authors:  M Martí-Carrizosa; F Sánchez-Reus; F March; E Cantón; P Coll
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

3.  Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.

Authors:  Maria Aigner; Thomas Erbeznik; Martin Gschwentner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Identification of Candida parapsilosis Sensu Lato in Pediatric Patients and Antifungal Susceptibility Testing.

Authors:  Maria Emilia Cattana; Catiana Dudiuk; Mariana Fernández; Florencia Rojas; Liliana Alegre; Susana Córdoba; Guillermo Garcia-Effron; Gustavo Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 6.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

Review 7.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

Review 8.  Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting.

Authors:  Brian D W Chow; Jennifer R Linden; Joseph M Bliss
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

9.  Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.

Authors:  Ana P Silva; Isabel M Miranda; Carmen Lisboa; Cidália Pina-Vaz; Acácio G Rodrigues
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

Review 10.  Anidulafungin, a new echinocandin: in vitro activity.

Authors:  Giulia Morace; Elisa Borghi; Roberta Iatta; Maria Teresa Montagna
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.